Moss, 21 March 2024
Due to private reasons the CEO of Gentian Diagnostics ASA, Hilja Ibert, has decided to resign from her position. Hilja has played a key role in the growth and success of Gentian Diagnostics ASA since 2018, and her dedication and contributions to the company over the past years has been outstanding.
However, following the resignation of Hilja Ibert the Nomination Committee is pleased to recommend her as a candidate for the position of new Chairperson of the Board. Her wealth of experience and strategic insights will continue to provide great value for Gentian Diagnostics ASA in this new capacity.
Simultaneously, Tomas Settevik, the Chairperson of the Board, has chosen not to stand for re-election. Tomas has been instrumental in guiding the board and the company. We express our thanks for his leadership of the past years.
The Company has initiated a search for Hilja Ibert´s replacement as CEO, in the meantime Gentian Diagnostics’ CFO, Njaal Kind, will serve as the acting CEO.
All the announced changes will take effect as of April 29, 2024, subject to the approval by the General Meeting.
IR contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525 (mobile)
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.